Pharmaceutical evaluation of glibenclamide products available in the Jordanian market | Zendy

Dina El-Sabawi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmaceutical evaluation of glibenclamide products available in the Jordanian market

Author(s) -

Dina El-Sabawi

Publication year - 2013

Publication title -

african journal of pharmacy and pharmacology

Language(s) - English

Resource type - Journals

ISSN - 1996-0816

DOI - 10.5897/ajpp2012.0014

Subject(s) - glibenclamide , pharmacopoeia , traditional medicine , dissolution , business , chemistry , pharmacology , mathematics , chromatography , medicine , alternative medicine , pathology , diabetes mellitus , endocrinology

®) which was obtained from the Saudi market was subjected to analysis and used as a reference product. All products were found satisfactory in terms of identification and related substances as per the BP requirements. However, the assay results showed that only two products, in addition to the reference (Daonil ® ) satisfied the BP specifications which required glibenclamide content to be within the range: 95 to 105% of the labeled content. All products, in spite of marginal deviations for two of them, were found to pass the United States Pharmacopoeia (USP) assay specifications (90 to 110%). Significant differences in dissolution behavior were observed between the different generics and the originator (Daonil ® ). Daonil ® exhibited the lowest dissolution profile while some products showed

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research